MaxCyte, Inc. (MXCT)

Over the past six months, MaxCyte's stock price has been impacted by several events. The Q4 2025 earnings report on March 24, 2026, missed EPS and revenue forecasts, leading to a stock drop. On March 23, 2026, Parmeet Ahuja was appointed as Chief Financial Officer. In February 2026, MaxCyte launched its ExPERT DTx™ 96-well electroporation platform. On March 16, 2026, MaxCyte received a Nasdaq non-compliance notice due to its stock price falling below $1.00 per share. MaxCyte is scheduled to report its first-quarter 2026 financial results on May 12, 2026. As of May 8, 2026, the stock has seen an 11.21% increase in the past month, but a 65.51% decrease over the last 12 months, and a year-to-date return of -45.94%.

MaxCyte's revenue model is structured to provide recurring revenue and high visibility through sales of instruments, disposable processing assemblies, consumables, annual instrument license fees, and potential milestone and sales-based payments. Demand can be influenced by customer-specific factors and broader market conditions rather than strict seasonality. MaxCyte's business is dependent on the adoption of its products by biopharmaceutical companies and academic institutions for their research and development activities in the cell and gene therapy market.

MaxCyte, Inc. is a clinical-stage cell therapy platform company specializing in cell engineering, operating in the biotechnology industry. Its core business revolves around its Flow Electroporation® technology, which facilitates the engineering of cells. MaxCyte's major products include the ExPERT™ platform, a portfolio of instruments designed for different scales of cell engineering. In addition to instruments, MaxCyte sells proprietary disposable processing assemblies, reagents, consumables, and software protocols and offers SeQure DX™ gene editing risk assessment services. MaxCyte generates revenue through instrument sales, consumables, licensing agreements, and potential payments from its Strategic Platform License model.

MaxCyte, Inc. is headquartered in Rockville, Maryland, USA, within Maryland's I-270 Biotech Corridor. The company maintains a global presence with offices and service centers located across North America, Europe, and Asia, and its ExPERT platform is available worldwide through international distributors.

MaxCyte has cultivated a positive brand reputation, particularly among its customers. Users of MaxCyte's ExPERT platform frequently praise the reliability of the equipment, the quality of customer service, and the user-friendly interface with well-established protocols. Customers have highlighted the platform's ability to achieve high knockdown efficiency in gene editing and its scalability for clinical programs. The company emphasizes its commitment to integrity, innovation, customer success, accountability, and a long-term focus. MaxCyte is also dedicated to fostering workplace development, diversity, and inclusion within its organization and the broader biotechnology industry.

MaxCyte, Inc. has a significant institutional ownership base. As of May 1, 2026, 121 institutional owners and shareholders have filed 13D/G or 13F forms, holding a total of 70,776,812 shares. Major institutional owners include BlackRock, Inc., Capricorn Fund Managers Ltd, Mirabella Financial Services Llp, Vanguard Group Inc, Vitruvian Partners LLP, Morgan Stanley, Mudita Advisors LLP, AXA Investment Managers S.A., BNP Paribas Asset Management Holding S.A., and Geode Capital Management, Llc. Institutional ownership accounts for 68.85% of the company, with individuals holding 1.51%.